[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620961":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":44,"collaborators":21,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":21,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":21,"enrollmentInfo":55,"targetDuration":21,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":21,"overallStatus":65,"whyStopped":21,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Onconic Therapeutics Inc.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"JPI-547 and Irinotecan","EXPERIMENTAL","coadministration of JPI-547 and Irinotecan",[13,14],"Drug: JPI-547","Drug: Irinotecan (drug)",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","JPI-547","The dose levels will be escalated following a 3+3 dose escalation scheme.",[9],null,{"type":17,"name":23,"description":19,"armGroupLabels":24,"otherNames":21},"Irinotecan (drug)",[9],[26],{"name":5,"role":27,"phone":28,"phoneExt":21,"email":29},"CONTACT","82-2-3454-0780","onconictherapeutics@gmail.com",[31],{"facility":32,"status":21,"city":33,"state":21,"zip":21,"country":34,"countryCode":21,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Severance Hospital, Yonsei Cancer Center, Yonsei University College of Medicine","Seoul","South Korea",{"type":36,"coordinates":37},"Point",[38,39],126.9784,37.566,{"lat":39,"lon":38},[42],{"name":43,"role":27,"phone":21,"phoneExt":21,"email":21},"SY Rha",{"type":45,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100620961","phase-1-to-evaluate-the-safety-and-tolerability-of-study-drug-as-a-third-line-and-beyond-therapy-for-recurrent-or-metastatic-gastric-cancer-100620961",false,"NCT07364422","To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b\u002F2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer","Inclusion Criteria:\n\n* Patients with recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after second-line therapy.\n* Those with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Those with at least one measurable lesion in accordance with RECIST 1.1\n\nExclusion Criteria:\n\n* Patients with a confirmed specific medical history or past surgical history\n* Patients who meet specific criteria regarding prior treatment\n* Patients with a history of specific drug administration\n* Patients with specific comorbidities.\n* Patients who have undergone major surgery within 4 weeks prior to screening or are expected to require major surgery during the clinical trial are excluded. (However, those who have had minor surgeries\n* Patients with symptoms at the time of screening, who have not received treatment, or who have rapidly progressing central nervous system (CNS) metastases.\n* Patients with mental disorders or altered mental status\u002Fconsciousness (AMS) that impair their ability to understand this clinical trial for informed consent.\n* Pregnant or Lactating Women\n* Subjects with a history of severe allergic anaphylactic reactions to the investigational product and\u002For its components, or who have contraindications to the administration of the investigational product and\u002For irinotecan\n* Patients considered unsuitable for this clinical trial by the investigator.","ALL","19 Years",{"count":56,"type":57},49,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE1","PHASE2","This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer",[64],"Gastric Cancer (GC)","NOT_YET_RECRUITING","2026-01-21",{"date":68,"type":69},"2026-01-23","ACTUAL",{"date":71,"type":57},"2026-02-27",{"date":73,"type":57},"2029-02-28",{"name":5,"class":6},1]